尾加压素II及其相关肽与受体在主动脉瓣狭窄中的作用
本研究探讨尾加压素II(UII)、尾加压素相关肽(URP)及其受体(UT)在主动脉瓣狭窄(AVS)发病机制中的作用。通过免疫组化和RT-PCR检测钙化与非钙化主动脉瓣中的表达,并用人主动脉瓣间质细胞进行功能实验。结果显示AVS患者中UII、URP和UT的mRNA表达显著增高,免疫染色与钙化和纤维化显著相关;UII或URP处理可促进细胞增殖、减少胆固醇外流、降低ABCA1蛋白表达并增加β-catenin核转位和矿物质沉积。提示尾加压素系统参与AVS发病,值得进一步研究。
要点
- AVS患者主动脉瓣中UII、URP和UT的mRNA表达显著升高。
- UII/URP免疫染色与瓣膜钙化和纤维化显著相关(P<.0001)。
- UII或URP处理人主动脉瓣间质细胞可促进增殖、减少胆固醇外流并增加矿化。
核心结论
- 尾加压素系统可能参与主动脉瓣狭窄的发病机制,值得进一步研究。
研究设计与样本
- 采用免疫组化和逆转录聚合酶链反应检测钙化与非钙化主动脉瓣中UII、URP和UT的细胞定位与mRNA表达。
- 从正常瓣膜分离人主动脉瓣间质细胞,分别用UII或URP处理,评估细胞增殖、胆固醇外流、钙沉积和β-catenin转位的变化。
主要发现
- AVS患者中UII、URP和UT的mRNA表达显著高于对照。
- 病变瓣膜中UII、URP和UT免疫染色丰富,且与钙化(P<.0001)和纤维化(P<.0001)显著相关。
- UII或URP处理人主动脉瓣间质细胞显著增加细胞增殖(P<.0001),降低胆固醇外流(分别为P=.0011和P=.0002)。
- UII显著降低ABCA1蛋白表达(P=.0457),增加β-catenin核转位(P<.0001)和矿物质沉积(P<.0001)。
临床怎么用
- 尾加压素系统可能成为主动脉瓣狭窄的潜在生物标志物或治疗靶点,但尚需临床验证。
局限性
- 研究为体外实验和組織表达分析,未明确因果关系及临床转化价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Aortic valve stenosis (AVS) is the most common cause of surgical valve replacement worldwide. The vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis and several other cardiovascular diseases; however, its role in the pathogenesis of AVS remains to be determined. Here, we investigated the expression of UII, urotensin-related peptide (URP), and the urotensin receptor (UT) and the role this system plays in AVS. METHODS: Immunohistochemistry and reverse-transcriptase polymerase chain reaction were used to examine the cellular localization and mRNA expression, of UII, URP, and UT in calcified and noncalcified aortic valves. Human aortic valve interstitial cells were isolated from normal valves and treated with UII or URP, and changes in cell proliferation, cholesterol efflux, calcium deposition, and β-catenin translocation were assessed. RESULTS: The mRNA expression of UII, URP, and UT was significantly greater in patients with AVS. There was abundant presence of UII, URP, and UT immunostaining in diseased compared with nondiseased valves and correlated significantly with presence of calcification (P < .0001) and fibrosis (P < .0001). Treating human aortic valve interstitial cells with UII or URP significantly increased cell proliferation (P < .0001) and decreased cholesterol efflux (P = .0011 and P = .0002, respectively). UII also significantly reduced ABCA1 protein expression (P = .0457) and increased β-catenin nuclear translocation (P < .0001) and mineral deposition (P < .0001). CONCLUSIONS: Together, these data suggest that the urotensin system plays a role in the pathogenesis of AVS and warrants further investigation.
引用
- Khan K, Albanese I, Yu B, et al. Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis. J Thorac Cardiovasc Surg. 2019. PMID: 31679703. doi:10.1016/j.jtcvs.2019.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。